Mirati Therapeutics Inc. has received FDA clearance of its IND application for MRTX-1133, a potent, oral small-molecule inhibitor of the KRAS G12D driver mutation.
Pancreatic cancer is an exceptionally lethal cancer that is notoriously treatment resistant, in part due to poor vascularization in the tumor microenvironment. Investigators working at the Moores Cancer Center at the University of California, San Diego (UCSD), reported in the Jan. 16, 2023, issue of Nature Cell Biology on the discovery of a pathway that was initiated by isolation stresses (e.g., hypoxia, nutrient deprivation, and/or lack of extracellular matrix, ECM) leading to this cellular transformation in the tumor-initiating pancreatic cancer cell.
Aptevo Therapeutics Inc. has filed a provisional patent with the U.S. Patent and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 bispecific antibody, APVO-711, with the potential to treat a range of solid malignancies such as head and neck squamous cell carcinoma, melanoma and carcinomas of the lung, gastrointestinal tract and colon.
A surgical team from the Curie-Montsouris Chest Center in Paris, has successfully performed thermal ablation of a metastatic lung lesion using microwaves via a computer tomography (CT)-guided endobronchial approach.
Chengdu Baiyu Pharmaceutical Co. Ltd. has identified piperazine derivatives acting as protein mono-ADP-ribosyltransferase TIPARP inhibitors reported to be useful for the treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has patented spiro compounds acting as tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer and cardiovascular and immunological disorders.
Several studies have indicated that volatile organic compounds (VOCs) in exhaled breath can be altered by lung cancer and serve as identifiable biomarkers. A limitation of using these VOCs as clinical biomarkers has been the fact that hundreds of such molecules are present in exhaled breath and it is experimentally challenging to monitor the molecular concentration changes of all the VOCs and further use them in lung cancer detection.
Several studies have indicated that volatile organic compounds (VOCs) in exhaled breath can be altered by lung cancer and serve as identifiable biomarkers. A limitation of using these VOCs as clinical biomarkers has been the fact that hundreds of such molecules are present in exhaled breath and it is experimentally challenging to monitor the molecular concentration changes of all the VOCs and further use them in lung cancer detection.
In a study published on Nov. 30, 2022, in PLOS One, researchers at the University of Louisville, Kentucky, and Indian Council of Agricultural Research (ICAR), New Delhi, analyzed the metabolic carbonyl compounds present in exhaled breath of the patients and developed a machine learning approach involving relevant VOC selection and use in cancer patient classification model training.
